Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01046214 · ClinicalTrials.gov registry record · Phase 1
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01046214: Clinical Trial Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01046214 is a Phase 1 study that was terminated before completion, run by Teva Pharmaceuticals USA. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01046214, a Phase 1 study, was terminated before completion, sponsored by Teva Pharmaceuticals USA.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.
Interventions
- DRUG Bupropion HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-01 |
| Phase | Phase 1 |
Why NCT01046214 stopped before completion
NCT01046214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Bupropion HCl is the first listed.
NCT01046214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01046214 about?
NCT01046214 is a clinical study titled "Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions". The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting condition...
What is the current status of trial NCT01046214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-01.
What interventions are being tested in trial NCT01046214?
The interventions under investigation include: Bupropion HCl (DRUG).
Who is sponsoring clinical trial NCT01046214?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01046214's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia